Liu, Xuewen

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 173

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 14